• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 40-17G filed by Daxor Corporation

    8/23/24 4:52:16 PM ET
    $DXR
    Medical/Dental Instruments
    Health Care
    Get the next $DXR alert in real time by email
    40-17G 1 form40-17g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 40-17G

    (Fidelity Bond filed pursuant to Rule 17g-1(g) (1) of the Investment Company Act of 1940)

     

    Investment Company Act File number 811-22684

     

    DAXOR CORPORATION

    (Exact name of registrant as specified in charter)

     

    107 Meco Lane

    Oak Ridge, TN 37830

    (Address of principal executive offices) (Zip code)

     

    Michael Feldschuh

    107 Meco Lane

    Oak Ridge, TN 37830

    (Name and address of agent for service)

     

    Registrant’s telephone number, including area code: 1-212-330-8500

     

    Date of fiscal year end: December 31, 2024

     

     

     

     

     

     

    Daxor Corporation

    107 Meco Lane

    Oak Ridge, TN 37830

     

    August 22, 2024

     

    Securities and Exchange Commission

    100 F Street, N.E.

    Washington, DC 20549

     

    Re: Daxor Corporation
      Investment Company Act of 1940 - Rule 17g-1(g)
      Bonding of Officers and Employees
      Daxor Corporation File No. 811-22684

     

    To Whom It May Concern:

     

    Pursuant to Rule 17g-1(g) under the Investment Company Act of 1940 (the “1940 Act”), enclosed herewith, please find a copy of the investment company bond (the “Bond”) in favor of Daxor Corporation, a management investment company registered under the 1940 Act. The term of the Bond is from the period of June 22, 2024 through June 22, 2025.

     

    Please call me at (212) 330-8504 should you have any questions.

     

    Very truly yours,

     

    /s/ Robert J. Michel  
    Robert J. Michel  

    Chief Financial Officer

    Chief Compliance Officer

    Corporate Secretary

     
    Principal Financial Officer  
    Principal Accounting Officer  
    Daxor Corporation  

     

     

     

     

    Daxor Corporation

     

    Secretary’s Certificate

     

    Rule 17g-1(g)(1)(A)(ii) - Copy of resolution approving the form and amount of the bond:

     

    I, Robert J. Michel, hereby certify that I am the duly elected and qualified Secretary of Daxor Corporation, a New York corporation (the “Corporation”). I further certify, in such capacity and on behalf of the Corporation, (1) that set forth below is a true, correct and complete copy of the resolutions duly adopted by the Board of Directors of the Corporation approving the amount and form of the fidelity bond adopted by vote of a majority of the members of the Board of Directors of the Corporation, including a majority of the directors who are not interested persons of the Corporation (within the meaning of Section 2(a)(19) of the Investment Company Act of 1940, as amended); and (2) that said resolutions have not been amended, modified or revoked, are in full force and effect as of the date hereof, and are the only resolutions relating to the matters covered thereby:

     

    NOW THEREFORE, BE IT RESOLVED, that the appropriate officers of the Corporation are authorized and directed to obtain the Fidelity Bond to provide coverage for each officer and employee of the Corporation who may singly, or jointly with others, have access to the securities or funds of the Corporation, either directly or through authority to draw upon such funds or to direct generally the disposition of those securities, in that amount approved or ratified by the Board from time to time.

     

    FURTHER RESOLVED, that the Board, including all directors who are not “interested persons” of the Board (as defined in the Investment Company Act of 1940), has determined that the form, terms and the amount of the Fidelity Bond (as presented and considered, covering, among others, officers and employees of the Corporation, in accordance with Rule 17g-1 under the Investment Company Act of 1940), are reasonable, after reviewing the terms of the Fidelity Bond and having given due consideration to, among other things, the estimated value of the aggregate assets of the Corporation to which any person covered under the Fidelity Bond may have access, the type and terms of the arrangements made for the custody and safekeeping of assets of the Corporation, and the nature of the securities held by the Corporation.

     

    FURTHER RESOLVED, that the Board, including a majority of the Board directors who are not “interested persons” of the Board (as defined in the Investment Company Act of 1940), at least annually will review the Fidelity Bond to determine whether the Fidelity Bond is reasonable in form and amount.

     

    FURTHER RESOLVED, that the appropriate officers of the Corporation be, and each of them acting alone hereby is, designated and directed to make the filings and give the notices required by Rule 17g-1 of the Investment Company Act of 1940, including all filings and notices required by Rule 17g-1(g).

     

    FURTHER RESOLVED, that, provided that the Fidelity Bond is issued in the form, in the amount, and with the terms described, the Fidelity Bond is approved by the Board, including all trustees who are not “interested persons” of the Board (as defined in the Investment Company Act of 1940).

     

    * * *

     

     

     

     

    IN WITNESS WHEREOF, I have signed my name, on this 22nd day of August 2024.

     

    Name: /s/ Robert J. Michel  
    Title: Robert J. Michel  
     

    Chief Financial Officer

     

      Chief Compliance Officer  
      Corporate Secretary  
      Principal Financial Officer  
      Principal Accounting Officer  
      Daxor Corporation  

     

     

     

     

     

     

     

    Get the next $DXR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DXR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

      Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients. The detection of true anemia and its management is a key part of Heart Failur

      5/14/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

      Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, announces the expansion of its innovative diagnostic solutions into two additional U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients nationwide. Daxor continues to drive healthcare transformation through its dual implementation models, tailored to meet the unique needs of diverse clinical settings. This strategic expansion includes: A premier regional r

      5/13/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

      Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision and enhancing treatment outcomes for a spectrum of conditions. The facility will utilize Daxor's state-of-the-art Tennessee-based CLIA-certified ezBVA Lab that delivers comprehensive b

      5/7/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    Leadership Updates

    Live Leadership Updates

    See more
    • Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer

      Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe

      6/5/24 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Daxor Corporation Appoints Linda Cooper, Vice President Project Management

      Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh

      2/17/23 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    Financials

    Live finance-specific insights

    See more
    • Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

      Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

      3/4/25 4:55:00 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

      Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio

      3/4/25 3:53:00 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

      Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw." — Anonymous As we forge ahead into this pivotal year, Daxor remains laser-focused on our mission, unwavering in our execution of strategic goals, and fueled by the relentless determination for transformative growth and adoption of our technology. 2024 was remarkable for the

      3/4/25 8:05:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Feldschuh Michael Richard bought $16,277 worth of Daxor Common Stock (2,063 units at $7.89), increasing direct ownership by 0.98% to 212,694 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      4/7/25 3:23:29 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Office Feldschuh Michael Richard bought $8,130 worth of Daxor Common Stock (1,000 units at $8.13), increasing direct ownership by 0.48% to 210,631 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      3/27/25 11:46:12 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Feldschuh Michael Richard bought $11,518 worth of Daxor Common Stock (1,492 units at $7.72), increasing direct ownership by 0.72% to 208,984 units (SEC Form 4)

      4/A - DAXOR CORP (0000027367) (Issuer)

      3/20/25 5:09:37 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Daxor Corporation

      DEF 14A - DAXOR CORP (0000027367) (Filer)

      6/6/25 2:28:16 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • SEC Form N-CEN filed by Daxor Corporation

      N-CEN - DAXOR CORP (0000027367) (Filer)

      3/14/25 4:49:36 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • SEC Form N-CSR filed by Daxor Corporation

      N-CSR - DAXOR CORP (0000027367) (Filer)

      3/3/25 5:26:05 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Feldschuh Michael Richard bought $16,277 worth of Daxor Common Stock (2,063 units at $7.89), increasing direct ownership by 0.98% to 212,694 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      4/7/25 3:23:29 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Office Feldschuh Michael Richard bought $8,130 worth of Daxor Common Stock (1,000 units at $8.13), increasing direct ownership by 0.48% to 210,631 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      3/27/25 11:46:12 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Feldschuh Michael Richard bought $11,518 worth of Daxor Common Stock (1,492 units at $7.72), increasing direct ownership by 0.72% to 208,984 units (SEC Form 4)

      4/A - DAXOR CORP (0000027367) (Issuer)

      3/20/25 5:09:37 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital initiated coverage on Daxor with a new price target

      Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00

      3/25/21 12:00:28 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care